股本结构
单位：万股
| 公告日期 | 2025-05-12 | 2025-03-24 | 2025-02-10 | 2025-05-12 | 2024-10-03 | 2024-11-12 |
|---|---|---|---|---|---|---|
| 证券总股本 | 2859.93 | 2859.93 | 2106.26 | 1745.28 | 1683.52 | 1337.41 |
| 普通股本 | 2859.93 | 2859.93 | 2106.26 | 1745.28 | 1683.52 | 1337.41 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-03-31 | 2025-03-17 | 2025-02-10 | 2024-12-31 | 2024-10-04 | 2024-09-30 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-05-12 | 2859.93 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Sale of common shares, net of financing costs
|
2025-03-31 |
| 2025-03-24 | 2859.93 | 未披露 | 定期报告 | 2025-03-17 |
| 2025-02-10 | 2106.26 | 未披露 |
更多>>
Common Stock Offered 3,609,755 shares of Common Stock by the company.
|
2025-02-10 |
| 2025-05-12 | 1745.28 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Sale of common shares, net of financing costs
Sale of common shares under at-the-market transactions, net of financing costs
Shares issued upon vesting of RSUs
Shares issued for consultant services
Redemption of Series A redeemable convertible preferred stock
|
2024-12-31 |
| 2024-10-03 | 1683.52 | 未披露 |
更多>>
On October 4, 2024 the company issued 3,461,138 common shares
|
2024-10-04 |
| 2024-11-12 | 1337.41 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Sale of common shares under at-the-market transactions, net of financing costs
|
2024-09-30 |
| 2024-09-25 | 1337.41 | 未披露 | 定期报告 | 2024-09-16 |
| 2024-08-09 | 1336.46 | 未披露 | 定期报告 | 2024-07-30 |
| 2024-08-08 | 1336.84 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Sale of common shares, net of financing costs
Shares issued upon vesting of RSUs
|
2024-06-30 |
| 2024-04-29 | 1336.46 | 未披露 | 定期报告 | 2024-04-29 |
| 2024-04-22 | 1335.00 | 未披露 | 定期报告 | 2024-04-16 |
| 2024-05-15 | 827.31 | 0.50 |
更多>>
From December 31, 2023 to March 31, 2024
Shares issued for consultant services
|
2024-03-31 |
| 2024-04-16 | 826.11 | 0.50 |
更多>>
From December 31,2022 to December 31,2023
Sale of common shares, net of financing costs
Shares issued upon vesting of RSUs
Shares issued for consultant services
|
2023-12-31 |
| 2023-11-09 | 826.08 | 0.50 |
更多>>
From June 30, 2023 to September 30, 2023
Shares issued upon vesting of RSU
Shares issued for consultant services
|
2023-09-30 |
| 2023-08-10 | 824.09 | 未披露 | 定期报告 | 2023-08-03 |
| 2023-07-24 | 824.11 | 未披露 |
更多>>
Oncocyte Corporation announced that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock.
|
2023-07-25 |
| 2023-05-15 | 16482.11 | 未披露 | 定期报告 | 2023-05-05 |
| 2023-05-01 | 16460.73 | 未披露 | 定期报告 | 2023-04-19 |
| 2023-04-06 | 16477.30 | 未披露 |
更多>>
Common stock offered 45,494,198 shares by the company
|
2023-04-05 |
| 2023-04-06 | 11927.88 | 未披露 | 定期报告 | 2023-04-02 |
| 2023-05-15 | 11927.90 | 0.0006 |
更多>>
From December 31, 2022 to March 31, 2023
Shares issued upon vesting of RSUs
|
2023-03-31 |
| 2023-04-12 | 11864.40 | 0.0006 |
更多>>
From December 31, 2021 to December 31, 2022
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Issuance of Series A redeemable convertible preferred stock, net of financing costs
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts
|
2022-12-31 |
| 2022-11-10 | 11864.38 | 未披露 | 定期报告 | 2022-11-03 |
| 2022-11-10 | 11861.90 | 0.0006 |
更多>>
From June 30, 2022 to September 30, 2022
Accretion of Series A convertible preferred stock to redemption value
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Stock-based compensation
|
2022-09-30 |
| 2022-08-12 | 11860.88 | 未披露 | 定期报告 | 2022-08-03 |
| 2022-08-12 | 11860.90 | 0.0006 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of Series A redeemable convertible preferred stock, net of financing costs
Accretion of Series A convertible preferred stock to redemption value
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
|
2022-06-30 |
| 2022-04-19 | 11851.30 | 未披露 |
更多>>
1.Common stock offered by 26,266,417 shares.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 92,246,604 shares of common stock outstanding as of April 13, 2022.
|
2022-04-19 |
| 2022-05-12 | 9224.70 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Sale of common shares, including at-the-market transactions
|
2022-03-31 |
| 2022-03-11 | 9224.66 | 未披露 | 定期报告 | 2022-03-03 |
| 2022-03-11 | 9223.20 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Sale of common shares, including at-the-market transactions
Stock options exercised
Warrants exercised
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes
Issuance of common stock as consideration for Razor Genomics acquisition
Issuance of common stock as consideration for Chronix Biomedical acquisition
|
2021-12-31 |
| 2021-11-09 | 9223.14 | 未披露 | 定期报告 | 2021-11-02 |
| 2021-11-09 | 9215.80 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Sale of common shares, including at-the-market transactions
Stock options exercised
Warrants exercised
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Stock-based compensation
Financing costs paid to issue common shares, including at-the-market transactions
|
2021-09-30 |
| 2021-08-11 | 9158.18 | 未披露 | 定期报告 | 2021-08-02 |
| 2021-07-14 | 9145.91 | 未披露 | 定期报告 | 2021-07-13 |
| 2021-08-11 | 9031.60 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Stock options exercised
Warrants exercised
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Issuance of common stock for Chronix Biomedical acquisition
|
2021-06-30 |
| 2021-06-14 | 8986.84 | 未披露 | 定期报告 | 2021-06-10 |
| 2021-05-21 | 8983.38 | 未披露 | 定期报告 | 2021-05-10 |
| 2021-05-21 | 8982.56 | 未披露 | 定期报告 | 2021-04-30 |
| 2021-05-17 | 8891.40 | 未披露 |
更多>>
From JANUARY 1, 2021 to March 31, 2021
Sale of common shares, including at-the-market transactions
Exercise of stock options
Exercise of warrants
Issuance of common stock to Razor Genomics
|
2021-03-31 |
| 2021-03-19 | 8891.41 | 未披露 | 定期报告 | 2021-03-09 |
| 2021-02-09 | 8644.18 | 未披露 |
更多>>
1.Common stock offered by the company 7,780,000 shares.
|
2021-02-09 |
| 2021-01-26 | 7866.18 | 未披露 |
更多>>
1.Common stock offered by the company 7,301,410 shares.
|
2021-01-26 |
| 2021-03-19 | 6911.70 | 未披露 |
更多>>
from December 31, 2019 to December 31, 2020
Sale of common shares
Sale of common shares under at-the-market transactions
Exercise of stock options
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Issuance of common stock in lieu of cash for payment of board fees and deferred salaries
Issuance of common stock as partial consideration for Insight Genetics, Inc. acquisition
|
2020-12-31 |
| 2021-01-21 | 6725.06 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Exercise of stock options
Stock-based compensation
Financing costs paid to issue common shares
|
2020-09-30 |
| 2020-07-29 | 6725.06 | 未披露 | 定期报告 | 2020-07-20 |
| 2020-07-29 | 6721.80 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Sale of common shares
Stock-based compensation
|
2020-06-30 |
| 2020-05-12 | 6721.79 | 未披露 | 定期报告 | 2020-05-07 |
| 2020-05-12 | 6248.40 | 未披露 |
更多>>
From JANUARY 1, 2020 to March 31, 2020
Sale of common shares
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes
Issuance of common stock for Insight Genetics, Inc. acquisition
|
2020-03-31 |
| 2020-03-26 | 6247.11 | 未披露 | 定期报告 | 2020-03-04 |
| 2020-03-26 | 5703.20 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Sale of common shares
Exercise of stock options
|
2019-12-31 |
| 2019-11-15 | 5703.17 | 未披露 | 定期报告 | 2019-11-15 |
| 2019-11-14 | 5197.28 | 未披露 | 定期报告 | 2019-10-29 |
| 2019-11-14 | 5197.30 | 未披露 |
更多>>
From JANUARY 1, 2019 to SEPTEMBER 30, 2019
Sale of common shares
Exercise of stock options
|
2019-09-30 |
| 2019-08-14 | 5197.28 | 未披露 | 定期报告 | 2019-07-31 |
| 2019-08-14 | 5197.30 | 未披露 |
更多>>
From January 1, 2019 to June 30, 2019
Sale of common shares
Exercise of stock options
|
2019-06-30 |
| 2019-05-14 | 5197.28 | 未披露 | 定期报告 | 2019-04-29 |
| 2019-05-14 | 5197.30 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Sale of common shares
Exercise of stock options
|
2019-03-31 |
| 2019-04-01 | 5197.28 | 未披露 | 定期报告 | 2019-03-04 |
| 2019-04-01 | 4066.40 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Sale of common shares and warrants
Exercise of stock options
|
2018-12-31 |
| 2018-11-13 | 4066.45 | 未披露 | 定期报告 | 2018-11-01 |
| 2018-11-13 | 4066.40 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-14 | 4066.45 | 未披露 | 定期报告 | 2018-08-08 |
| 2018-07-30 | 3940.76 | 未披露 | 定期报告 | 2018-07-12 |
| 2018-08-14 | 3940.80 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-15 | 3940.51 | 未披露 | 定期报告 | 2018-05-10 |
| 2018-05-15 | 3781.80 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-04-02 | 3146.86 | 未披露 | 定期报告 | 2018-03-20 |
| 2018-04-02 | 3145.20 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of common stock upon exercise of 2016 warrants
Exercise of stock options
|
2017-12-31 |
| 2017-11-14 | 3142.71 | 未披露 | 定期报告 | 2017-11-01 |
| 2017-11-14 | 3141.70 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-14 | 3133.65 | 未披露 | 定期报告 | 2017-08-07 |
| 2017-08-14 | 2952.00 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-04-28 | 2936.85 | 未披露 | 定期报告 | 2017-04-16 |
| 2017-04-28 | 2936.70 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-02-27 | 2936.16 | 未披露 | 定期报告 | 2017-02-17 |
| 2017-02-27 | 2873.70 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Proceeds from issuance of common stock and warrants, net of discounts and financing costs
Exercise of stock options
|
2016-12-31 |
| 2016-11-10 | 2870.93 | 未披露 | 定期报告 | 2016-10-27 |
| 2016-11-10 | 2867.70 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-09-26 | 2867.73 | 未披露 | 定期报告 | 2016-08-29 |
| 2016-08-11 | 2543.12 | 未披露 | 定期报告 | 2016-08-10 |
| 2016-08-11 | 2543.10 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-16 | 2543.12 | 未披露 | 定期报告 | 2016-05-09 |
| 2016-04-29 | 2543.08 | 未披露 | 定期报告 | 2016-04-27 |
| 2016-05-16 | 2541.20 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-30 | 2541.18 | 未披露 | 定期报告 | 2016-03-23 |
| 2016-01-04 | 2539.10 | 未披露 |
更多>>
Following the completion of the Distribution and based on the number of shares of our capital stock outstanding as of December 10, 2015, we will have a total of 25,390,967 shares of our common stock outstanding
|
2016-01-04 |
| 2016-03-30 | 2539.10 | 未披露 |
更多>>
From December 31, 2014 to December 31, 2015
Common stock issued to BioTime for extinguishment of debt
Common stock issued to investors for cash
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest of $18
Common stock issued to BioTime for cash
Exercise of stock options
OncoCyte common stock received as a dividend in kind from BioTime
|
2015-12-31 |
| 2015-11-23 | 2391.40 | 未披露 |
更多>>
from JANUARY 1, 2015 to SEPTEMBER 30, 2015
Issuance of common stock for cash to investors
Issuance of common stock for partial payment of related party amounts due to BioTime
Issuance of common stock for cash to BioTime
|
2015-09-30 |
From December 31, 2024 to March 31, 2025
Sale of common shares, net of financing costs
Common Stock Offered 3,609,755 shares of Common Stock by the company.
From December 31, 2023 to December 31, 2024
Sale of common shares, net of financing costs
Sale of common shares under at-the-market transactions, net of financing costs
Shares issued upon vesting of RSUs
Shares issued for consultant services
Redemption of Series A redeemable convertible preferred stock
On October 4, 2024 the company issued 3,461,138 common shares
From June 30, 2024 to September 30, 2024
Sale of common shares under at-the-market transactions, net of financing costs
From March 31, 2024 to June 30, 2024
Sale of common shares, net of financing costs
Shares issued upon vesting of RSUs
From December 31, 2023 to March 31, 2024
Shares issued for consultant services
From December 31,2022 to December 31,2023
Sale of common shares, net of financing costs
Shares issued upon vesting of RSUs
Shares issued for consultant services
From June 30, 2023 to September 30, 2023
Shares issued upon vesting of RSU
Shares issued for consultant services
Oncocyte Corporation announced that the Company will implement a 1-for-20 reverse stock split of the outstanding shares of its common stock.
Common stock offered 45,494,198 shares by the company
From December 31, 2022 to March 31, 2023
Shares issued upon vesting of RSUs
From December 31, 2021 to December 31, 2022
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Issuance of Series A redeemable convertible preferred stock, net of financing costs
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts
From June 30, 2022 to September 30, 2022
Accretion of Series A convertible preferred stock to redemption value
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Stock-based compensation
From March 31, 2022 to June 30, 2022
Issuance of Series A redeemable convertible preferred stock, net of financing costs
Accretion of Series A convertible preferred stock to redemption value
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
1.Common stock offered by 26,266,417 shares.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 92,246,604 shares of common stock outstanding as of April 13, 2022.
From December 31, 2021 to March 31, 2022
Sale of common shares, including at-the-market transactions
From December 31, 2020 to December 31, 2021
Sale of common shares, including at-the-market transactions
Stock options exercised
Warrants exercised
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes
Issuance of common stock as consideration for Razor Genomics acquisition
Issuance of common stock as consideration for Chronix Biomedical acquisition
From June 30, 2021 to September 30, 2021
Sale of common shares, including at-the-market transactions
Stock options exercised
Warrants exercised
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Stock-based compensation
Financing costs paid to issue common shares, including at-the-market transactions
From March 31, 2021 to June 30, 2021
Stock options exercised
Warrants exercised
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Issuance of common stock for Chronix Biomedical acquisition
From JANUARY 1, 2021 to March 31, 2021
Sale of common shares, including at-the-market transactions
Exercise of stock options
Exercise of warrants
Issuance of common stock to Razor Genomics
1.Common stock offered by the company 7,780,000 shares.
1.Common stock offered by the company 7,301,410 shares.
from December 31, 2019 to December 31, 2020
Sale of common shares
Sale of common shares under at-the-market transactions
Exercise of stock options
Shares issued upon vesting of RSU, net of shares retired to pay employees’ taxes
Issuance of common stock in lieu of cash for payment of board fees and deferred salaries
Issuance of common stock as partial consideration for Insight Genetics, Inc. acquisition
From June 30, 2020 to September 30, 2020
Exercise of stock options
Stock-based compensation
Financing costs paid to issue common shares
From March 31, 2020 to June 30, 2020
Sale of common shares
Stock-based compensation
From JANUARY 1, 2020 to March 31, 2020
Sale of common shares
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes
Issuance of common stock for Insight Genetics, Inc. acquisition
from December 31, 2018 to December 31, 2019
Sale of common shares
Exercise of stock options
From JANUARY 1, 2019 to SEPTEMBER 30, 2019
Sale of common shares
Exercise of stock options
From January 1, 2019 to June 30, 2019
Sale of common shares
Exercise of stock options
from December 31, 2018 to March 31, 2019
Sale of common shares
Exercise of stock options
from December 31, 2017 to December 31, 2018
Sale of common shares and warrants
Exercise of stock options
from December 31, 2016 to December 31, 2017
Issuance of common stock upon exercise of 2016 warrants
Exercise of stock options
from December 31, 2015 to December 31, 2016
Proceeds from issuance of common stock and warrants, net of discounts and financing costs
Exercise of stock options
Following the completion of the Distribution and based on the number of shares of our capital stock outstanding as of December 10, 2015, we will have a total of 25,390,967 shares of our common stock outstanding
From December 31, 2014 to December 31, 2015
Common stock issued to BioTime for extinguishment of debt
Common stock issued to investors for cash
Common stock issued to BioTime upon conversion of BioTime convertible note payable and accrued interest of $18
Common stock issued to BioTime for cash
Exercise of stock options
OncoCyte common stock received as a dividend in kind from BioTime
from JANUARY 1, 2015 to SEPTEMBER 30, 2015
Issuance of common stock for cash to investors
Issuance of common stock for partial payment of related party amounts due to BioTime
Issuance of common stock for cash to BioTime